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ABSTRACT 
Background: Patients with adult congenital heart disease (ACHD) have an increased risk of 
arrhythmic, sudden cardiac death. The subcutaneous implantable cardioverter defibrillator (S-ICD) 
provides a potentially safer alternative to transvenous ICDs in ACHD. Suitability for S-ICD depends on 
the surface ECG which is often abnormal in ACHD patients. This study investigates the proportion of 
ACHD patients who meet the screening criteria for S-ICD 
 
Methods A standard screening ECG was performed in 102 patients with  complex ACHD (Tetralogy of 
Fallot, Fontan Circulation, Transposition of the Great Arteries). This process was repeated post-
exercise for patients who also had an exercise test.  
Results: Three quarters (75.4%) of ACHD patients meet screening criteria for an S-ICD with at least 1 
suitable vector. The most common number of acceptable vectors in the eligible group was 2 (35% of 
total population). In only 12% were all three vectors suitable whilst 28% had only 1. The primary 
vector (equivalent of ECG lead III) was the most common suitable vector, found in 62% of 
participants who had appropriate sensing vectors. 25 (24.5%) patients failed to meet the S-ICD 
screening criteria. Of these, 14 had repaired tetralogy of Fallot. 92% of patients with a Fontan 
circulation met ECG screening criteria. Of those who had the protocol repeated following their 
cardiopulmonary exercise test (n=14), only 1 additional patient failed eligibility criteria. 
Conclusions: A quarter of ACHD patients do not meet eligibility criteria for the S-ICD. However, more 
than 90% of patients with a Fontan circulation are suitable for an S-ICD.   
 
 
 
 
Keywords: subcutaneous implantable cardioverter-defibrillator; adult congenital heart disease, 
Fontan circulation; Tetralogy of Fallot 
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INTRODUCTION 
Patients with adult congenital heart disease (ACHD) have an increased risk of sudden cardiac death 
due to tachyarrhythmias. Those most at risk are patients with repaired tetralogy of Fallot (TOF)
 1 
and 
complete transposition of the great arteries (d-TGA)
 2 
and Fontan circulation
3
. The 2014 HRC/PACES 
guidelines
4
 recommend implantable cardioverter defibrillator (ICD) implantation in ACHD patients 
with poor systemic ventricular function, following hemodynamically significant ventricular 
arrhythmias and in selected higher risk patients with TOF. Unfortunately, transvenous ICD 
implantation can be challenging in the ACHD population, as a result of their complex anatomy and 
associated risks of procedural complications
5
. Particular difficulty exists following the Fontan 
procedure for single ventricle, which often precludes access from the venous system to the heart
6
. 
Systemic venous pathway obstruction has also been reported in 36% of d-TGA patients
7
. In addition, 
lead failure, resulting from growth-related lead distortion, is common, with incidence rates as high 
as 26%
8
.  
 
The most recent development in ICD design is the subcutaneous ICD (S-ICD) system, which 
comprises of a generator placed in the anterolateral position and a left parasternal coil placement. 
The absence of transvenous access preserves the vasculature and is thought to minimise procedure-
related complications, risk of bleeding, thrombosis and infection
5
. The S-ICD is an attractive option in 
ACHD patients who are likely to require multiple generator changes in their lifetime and face 
potential complications with each intervention, particularly when transvenous access to the 
ventricles is difficult. Their use in this population is recommended by the European Society of 
Cardiology
9
. 
 
ACHD patients frequently have abnormal ECGs which may interfere with appropriate sensing and is 
unclear what proportion would be suitable for an S-ICD.  Prior to S-ICD implantation ECG screening 
must be performed to ensure that T waves are not oversensed and shocks are delivered 
appropriately. This involves assessment of an appropriate R to T (R:T) wave ratio. Screening data for 
ACHD patients is limited and only small sample studies of around 30 patients have so far been 
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carried out, with reported ineligibility rates between 13.3%
10
 and 48.4% 
11
. Independent predictors 
of ineligibility include prolonged QRS duration, a R:Tmax value of less than 3
12
 and T wave inversion
13
.  
This study investigates what proportion of patients with ACHD meet the ECG screening criteria for an 
S-ICD.  
 
METHODS 
In this prospective study, patients were recruited from the ACHD patient population in a large 
quaternary specialist ACHD centre (Queen Elizabeth Hospital, Birmingham, United Kingdom). 
Participants were recruited opportunistically during routine attendance at the ACHD outpatient 
clinic. Inclusion criteria were: males and females of any race or ethnic origin, age ≥ 16 years and a 
diagnosis/clinical history of TOF, d-TGA or Fontan palliation. Exclusion criteria were: age <16 years 
and a lack of capacity to provide informed consent. Approval was granted by Health Research 
Authority and an independent review board at the West Midlands, Edgbaston Research Ethics 
Committee (REC 16/WM/0255). 
 
Study design 
The screening ECG was carried out according to the S-ICD manufacturer’s protocol14, which involves 
using modified electrode positions of 3 ECG electrodes (Figure 1). Up to 10 seconds of ECG was 
recorded (25 mm/s) at a gain of 5, 10 or 20 mm/mV, in the supine, sitting and standing postures.  
Three vectors were analysed, namely primary, secondary and alternate vectors (Figure 1). This 
process was repeated post-exercise for patients who also had a cardiopulmonary exercise test as 
part of their routine ACHD investigations. Analysis of the subsequent electrical vectors was 
undertaken using the patient screening tool (Model 4744, Boston Scientific, St Paul, US) 
14
 (Figure 2). 
Demographic information and clinical data was recorded for all ACHD participants and ECG data was 
extracted from their most recent 12-lead ECG.  The R:Tmax was defined as the ratio of the R wave to T 
wave in the lead with the largest amplitude T wave.  
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Statistical analysis 
For analysis of clinical and electrographic features, categorical data is expressed as percentages and 
were analysed using the Fisher’s exact test. Continuous data was assessed using the Kolmogorov-
Smirnov test and expressed, depending on its normality. For normally distributed data, the mean 
and SD were calculated and an independent t-test was used. For data that was not normally 
distributed, the median and interquartile range (IQR) was calculated and compared using the Mann-
Whitney U-Test. The statistics software package SPSS 22.0 (IBM, Armonk, NY, USA) was used for data 
collection and analysis.  
RESULTS 
A total of 107 ACHD patients were recruited. Of these, 5 (4.6%) patients were excluded due to a lack 
of ECG data in all three postures or at additional gain settings. The complete screening ECG was 
obtained in 102 participants, 14 (13.7%) of whom also had the protocol repeated post-exercise. As 
shown in Table 1, the mean age was 30.7 (± 1.19) years (mean ± SD) and 54 (53.0%) were female. In 
addition to their primary diagnosis, 5 (4.9%) patients also had dextrocardia, 61 (59.8%) had a bundle 
branch block, of which 83.6% were right bundle branch block.  
 
Eligibility. A total of 77 (75.4%) patients were deemed potentially eligible for an SICD with at least 1 
suitable vector. The primary vector was the most common suitable vector found in 48 (62%) 
participants who had appropriate sensing vectors. The most common number of acceptable vectors 
in the eligible group was 2 (n=36, 47%), whereas only 12 (16%) had all 3 acceptable vectors and 29 
(38%) had only one suitable vector.  
 
A total of 25 (24.5%) patients failed to meet the S-ICD ECG screening criteria and were deemed 
ineligible. Of these, 14 (56%) had a diagnosis of TOF. The disease distribution for the ineligible group 
is summarised in Figure 3. In contrast, 26/28 (93%) of patients with a Fontan circulation would be 
suitable for an SICD on the basis of ECG screening. Of those who had the screening ECG repeated 
following their cardiopulmonary exercise test (n=14), only 1 additional patient (with TOF) failed to 
maintain their eligibility.  
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Reasons for ineligibility. Only 1 Fontan patient was deemed ineligible (p=0.01). In contrast over a 
third (n=14, 36%) of patients with tetralogy of Fallot were ineligible p=0.001). The measured R:Tmax 
ratio was significantly smaller in the ineligible group (p=0.03), with a mean value of 1.8 for the 
ineligible group and 2.9 for the eligible group. The QRS duration in the ineligible group was 
significantly broader (p=0.01) with a greater proportion having RBBB rather than LBBB morphology 
(p<0.01). Consequently, the number of patients with a narrow QRS was significantly lower in the 
ineligible group (p=0.02). 
A tall T wave was the only reason for no acceptable vectors in all postures (n=13), and for the 12 
patients who had an acceptable vector in at least 1 posture, the main reason for failure in all three 
postures was a change in the R:Tmax. For both groups, the R wave changed significantly with different 
postures and was lowest in the sitting position (Figure 4). 
 
DISCUSSION 
 
This study shows that nearly a quarter of ACHD patients fail to meet the standard ECG screening 
criteria for the S-ICD. Eligibility was lowest in patients with TOF and highest in patients with a Fontan 
circulation. The use of SICD in the congenital population is not widely reported in the literature. 
Moore et al. reported the use of SICD in 21 ACHD patients 9 with Fontan circulation, largely for 
primary prevention. The main indication for a subcutaneous approach was inability to access a non-
systemic ventricle percutaneously. Overall the SICDs function well but there was a 15% 
inappropriate shock rate .
15
 Ferro et al. showed similar outcomes in 8 patients with SICD and adult 
congenital heart disease in the secondary prevention setting.
16
 The main reason for this approach 
was the inability to implant a standard ICD percutaneously. This group showed a similar 
inappropriate shock rate (12.5%) 
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Effect of disease 
Nordkamp et al 
12
 found an S-ICD ineligibility rate of 7.4% in the general cardiac population based on 
ECG screening. The significantly higher ineligibility rates in the ACHD population seen in this study 
may be due to abnormal T wave morphology 
17
 resulting from structural and functional disturbances 
that characterises ACHD, including cardiac chamber enlargement, abnormal cardiac position, 
mechanical strain and augmented repolarisation 
18
.  
 
Ineligibility was highest in patients with TOF. This is perhaps not unexpected, as patients with TOF 
may have RV dilatation due to volume overload resulting from pulmonary regurgitation
19
.  
Moreover, TOF patients also have conduction abnormalities and frequently have prolonged QRS 
complexes. Indeed QRS duration is one of the major criteria for predicting the risk of SCD and 
arrhythmia in patients with TOF
4
. Patients with TOF are at particularly high risk of monomorphic 
ventricular tachycardia, which often responds to anti-tachycardia pacing (ATP). For this reason also 
transvenous ICD may be preferable to an S-ICD in patients with TOF. 
 
In contrast, we found that up to 93% of patients with a Fontan circulation met ECG eligibility criteria. 
An S-ICD may be particularly useful in the Fontan population as the surgical repair usually precludes 
access to the ventricles from the systemic venous circulation. Often the only practical approach to 
place an ICD would either be a high risk surgical procedure 
20
 or an S-ICD.  
It is possible that the number of ACHD patients suitable for S-ICD might be increased by alternative 
placement of electrodes, in a right parasternal position. This reduces the amplitude of the T waves 
without reducing the sensitivity of the R wave.  Wilson et al. showed that there was no reduction in 
the R wave or T wave using the right parasternal  position  to screen compared to the standard 
technique in a mixed group of congenital patients (TOF, transposition and single ventricle).
21 
There 
was, however, a significant reduction in these vectors in control patients.  Alonzo et al screened 102 
patients with TOF and found 34% were ineligible for SICD with standard screening but only 25% were 
ineligible with right sided screening.
22 
The highest rates of ineligibility were found in those patients 
with the most risk factors for sudden death. In contrast, they found no additional benefit of right 
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sided screening in patients with a single ventricle.  Okamura et al.
23
 showed a much lower rate of 
ineligibility (21%) using standard screening in a cohort of 100 ACHD patients. This was reduced to 
12% by right sided screening. However the vast majority of their patients had simple rather than 
complex congenital heart disease and only 22 had TOF.  In summary right sided placement of an ICD 
may allow a higher proportion of ACHD patient to be eligible for an SICD, particularly those with TOF 
but may pose difficulties in the patients require further sternotomies. The benefit in other types of 
congenital heart disease appears limited. 
  
Effect of posture 
This study shows that significant proportion of ACHD patients have acceptable vectors in one or two 
postures, but were ultimately deemed ineligible due to altered R:T upon change in posture, which 
resulted in the R or T wave falling outside the screening template. This highlights the sensitivity of 
the subcutaneous sensing electrode to variations in QRS morphology with cardiac orientation. 
Together with significant changes in R wave amplitude seen across all three postures, this supports 
screening in multiple positions as a prerequisite for identifying such changes that could affect the 
function of the S-ICD. 
 
Exercise 
Kooiman et al 
24
 suggested that exercise would render a large proportion of patients ineligible, as a 
result of exercise-induced changes in QRS and T wave morphology. Although only a small proportion 
of patients underwent exercise testing in this study, it only had a small impact on eligibility in 
patients with ACHD.  
 
Limitations 
This study only included the most common forms of ACHD for whom an ICD may be indicated; 
others such as atrioventricular septal defects, or Ebstein’s anomaly were excluded. Only standard 
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ECG screening was performed, right parasternal lead positions were not assessed which may have 
improved eligibility. Only a small proportion of patients underwent exercise testing. 
 
CONCLUSIONS 
Patients with ACHD are at increased risk of ventricular arrhythmias and sudden death but the use of 
transvenous ICDs can be difficult because of the complex venous anatomy and high complication 
rates. They would appear to be good candidates for S-ICD. This study demonstrates that using 
standard ECG screening, nearly a quarter of patients with the commonest ACHD indications for ICD 
are not candidates for the S-ICD, due to a risk of inappropriate sensing. In contrast, the vast majority 
of patients with a Fontan circulation are suitable. In these patients placing a transvenous ICD lead is 
usually not possible and S-ICD offers a relatively low risk approach to allow ICD therapy.  Whilst 
improvements to the current screening protocol are expected, they are unlikely to have a significant 
impact on eligibility without substantial development of the current S-ICD sensing algorithm.  
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FIGURE LEGENDS 
 
Figure 1. Modified position of the ECG electrodes used for the S-ICD ECG screening protocol. * 
*, adapted from Boston Scientific 
14.
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Figure 2a. Patient ECG screening tool. The figure shows the patient ECG screening tool (Model 4744, 
Boston Scientific, St Paul, US)
 14
 and the correct alignment of the QRS within a suitable template. 
According to the required method, the QRS complex and prevailing T wave must fit into any one of 
the templates shown. In the example shown, the patient was considered suitable for S-ICD as there 
was a minimum of 1 acceptable sensing vector in all postures.  
 
 
Figure 2b Example ECGs (I) a screening ECG that fits into one of the screening templates and was 
deemed eligible. (II) a screening ECG that failed to meet criteria based as a result of the tall T wave 
and small R:T ratio.  
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Figure 3a. Disease distribution within the ineligible group. 
 
Figure 3b. Proportion of patients deemed suitable for S-ICD for each of the diagnosis. TOF – repaired 
tetralogy of Fallot, TGA – transposition of the great arteries, Fontan – Fontan repair for single 
ventricle. 
 
 
 
Figure 4. Change in measured R wave amplitude seen across the postures, in both the eligible and 
ineligible group. 
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Table 1. Characteristics of the study group. 
 
All patients 
(N = 102) 
Eligible 
(N = 77) 
Ineligible  
(N = 25) 
P value 
Age (years) 30.7 ±1.19 30.1 ± 11.1 32.6 ± 14.6 0.849 
Sex (female) 54 (53.0%) 43 (55.8%) 11 (44.0%) 0.360 
BMI (kg/m²) 25.2 ±5.85 25.4 ± 6.35 24.6 ± 3.70 0.904 
     
Aetiology     
   Fontan 22 (21.6%) 21 (27.3%) 1 (4.0%) 0.016 
   TGA 35 (34.3%) 26 (33.8%) 9 (36.0%) 0.841 
   TOF 39 (38.2%) 25 (32.5%) 14 (56.0%) 0.038 
   Fontan + TGA 5 (4.9%) 5 (6.5%) 0 0.194 
   TOF + Fontan 1 (1%) 0 1 (4%) 0.081 
     
ECG variables     
PR interval (ms) 162.0 ± (35.2) 161.5 ± 36.1 160.6 ± 32.0 0.993 
QRS morphology     
   LBBB 10 (9.8%) 7 (9.1%) 3 (12.0%) 0.673 
   RBBB 51 (50%) 34 (44.2%) 17 (68.0%) 0.041 
QRS duration (ms) 130 ± 31.48 121.5 ± 30.8 148.6 ± 32.5 <0.001 
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Narrow QRS (<120 ms) 41 (40.2%) 36 (46.8%) 5 (20.0%) 0.020 
QTc (ms) 455 ± 40.41 450.8 ± 40.5 467.9 ± 38.0 0.065 
R wave (mV)     
      Supine  18.4 ± 10.08 19.2 ± 9.06 16.1 ± 12.7 0.013 
      Sitting  17.0 ± 9.83 18.0 ± 8.83 14.1 ± 12.2 0.083 
      Standing  17.6  ± 9.80 18.3 ± 8.85 15.1 ± 12.2 0.145 
      R:Tmax 2.61 ± 2.15 2.87 ± 2.33 1.79 ± 1.11 0.034 
Continuous data provided as mean ± SD. p values refer to differences between eligible and ineligible 
groups. BMI = body mass index, RBBB = right bundle branch block, LBBB = left bundle branch block, 
R:Tmax= R:T on the maximum T wave, SVEF = ejection fraction, TGA = transposition of the great 
arteries, TOF = tetralogy of Fallot 
 
